- ONCOLOGIE & HEMATOLOGIE
DOMAINES THERAPEUTIQUES :
Bemarituzumab
anti-FGFR2b Antibody
Phase 1b/2
Monotherapy
Indication
Solid Tumors with
FGFR2b Overexpression
Solid Tumors with
FGFR2b Overexpression
A Phase 1b/2, multicenter, Open-label Basket Study evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression
Amgen protocol ID 20210104
Bemarituzumab
anti-FGFR2b Antibody
Phase 1b/3
Combination therapy
mFOLFOX6 + nivolumab
mFOLFOX6 + nivolumab
Indication
Gastric or GEJ cancer
Gastric or GEJ cancer
Bemarituzumab plus chemotherapy and nivolumab versus chemotherapy and nivolumab alone in subjects with previously untreated advanced G/GEJ cancer with FGFR2b overexpression
Amgen protocol ID 20210098
Status Switzerland
Recruiting
Sotorasib
KRAS G12C Inhibitor
Phase 3
Combination therapy
platinum doublet
platinum doublet
Indication
NSCLC
NSCLC
Sotorasib platinum doublet combination versus pembrolizumab platinum doublet combination as a front-line therapy in participants with stage IV or advanced stage IIIB/C nonsquamous Non-Small Cell Lung Cancer, negative for PD-L1
Amgen protocol ID 20190341
Tarlatamab
(AMG 757)
(AMG 757)
DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 1b
Combination therapy
carboplatin,
etoposide + PD-L1 inhibitor
carboplatin,
etoposide + PD-L1 inhibitor
Indication
ES-SCLC
ES-SCLC
A Phase 1b Study Evaluating the Safety and Efficacy of First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Patients With Extensive-Stage Small Cell Lung Cancer
Amgen protocol ID 20200469
Tarlatamab
(AMG 757)
(AMG 757)
DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 3
Monotherapy
Indication
ES-SCLC
ES-SCLC
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Amgen protocol ID 20210004
Status Switzerland
Recruiting
Tarlatamab
(AMG 757)
(AMG 757)
DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 1
Combination therapy
+/- pembrolizumab
+/- pembrolizumab
Indication
SCLC
SCLC
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Amgen protocol ID 20160323
AMG 794
CLDN6 x CD3 Half-life extended Bispecific T-Cell Engager
Phase 1
Monotherapy
Indication
CLDN6 positive
solid tumors
CLDN6 positive
solid tumors
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Subjects With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other
Malignant Solid Tumor Indications
Amgen protocol ID 20210007
AMG 193
MTA-Cooperative PRMT5 inhibitor
Phase 1, 1b, 2
Combination therapy
+/- Docetaxel
+/- Docetaxel
Indication
MTAP-deleted solid tumors
MTAP-deleted solid tumors
A Phase 1/1b/2 Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-Null Solid Tumors
Amgen protocol ID 20210023
Xaluritamig
(AMG 509)
(AMG 509)
anti-STEAP1 XmAb
Phase 1
Mono- and combination therapy
Indication
mCRCP
mCRCP
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Amgen protocol ID 20180146
Status Switzerland
Recruiting
For further questions relating to the study programme, please contact Carine Bast